PAUL NEUREITER — Lobbyist Profile | Poliscope

PAUL NEUREITER

Filings

Clients

Firms

Years active

2016–2016

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
AMGEN, INC.	3	2016

Firm	Filings	Years
AMGEN, INC.	3	2016

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

Preserve Access to Affordable Generics Act

Cited source text

Trans-Pacific Partnership (12 years data exclusivity) Patent Settlements, S. 2019, the Preserve Access to Affordable Generics Act

Preserve Access to Affordable Generics Act

Cited source text

Trans-Pacific Partnership (12 years data exclusivity) Patent Settlements, S. 2019, the Preserve Access to Affordable Generics Act

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

2016 · fourth_quarter · Q4

Firm income: —Client expense: $2,280,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

CPT

Trans-Pacific Partnership (12 years data exclusivity) Patent Settlements, S. 2019, the Preserve Access to Affordable Generics Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2016 · third_quarter · Q3

Firm income: —Client expense: $2,920,000